LEANDRO RESENDE | Oncology and precision medicine | Innovative Research Award

Published on by Oncology

Innovative Research Award

LEANDRO RESENDE
Rede Dor

LEANDRO RESENDE
Affiliation Rede Dor
Country Brazil
Scopus ID 57188977624
Documents 5
Citations 35
h-index 3
Subject Area Oncology and precision medicine
Event International Research Awards on Oncology and Cancer Research
Scopus Author Profile

LEANDRO RESENDE is a researcher affiliated with Rede Dor in Brazil whose documented scholarly profile is associated with oncology and precision medicine.The Innovative Research Award profile presents this research activity within the broader context of contemporary cancer science, where molecular characterization, individualized treatment strategies, biomarkers, and evidence-based clinical decision-making increasingly intersect. Precision oncology seeks to connect biological information with clinically meaningful therapeutic choices. [1]

Abstract

The Innovative Research Award profile recognizes the research record of LEANDRO RESENDE, affiliated with Rede Dor, Brazil, in the field of oncology and precision medicine. The documented Scopus profile reports five scholarly documents, 35 citations, and an h-index of 3. [1] These indicators provide a bibliometric snapshot of published research and citation activity.Within modern oncology, precision medicine emphasizes the integration of molecular, clinical, and pathological information to support more individualized approaches to cancer investigation and treatment.

Keywords

  • Innovative Research Award
  • Oncology
  • Precision Medicine
  • Cancer Research
  • Biomedical Research
  • Research Impact

Introduction

Cancer research increasingly depends on interdisciplinary approaches that connect molecular biology, clinical medicine, pathology, genomics, and computational analysis. Precision medicine has developed as an important framework for identifying biological differences between tumors and using those differences to inform research and therapeutic strategies. [3]Against this background, researchers working across oncology contribute to a continually expanding evidence base.

Research Profile

LEANDRO RESENDE is affiliated with Rede Dor in Brazil and is represented in Scopus under Author ID 57188977624. The supplied profile records five documents, 35 citations, and an h-index of 3. [1] The stated subject area is oncology and precision medicine, placing the research profile within a clinically and scientifically significant field.

Research Contributions

Contemporary cancer frameworks emphasize multiple interacting characteristics of malignant disease, including genomic instability, cellular signaling, immune interactions, and the tumor microenvironment. [3]The documented bibliometric record offers measurable evidence of scholarly dissemination, while the specific scientific significance of individual publications should be evaluated through their methods, findings, citations, and subsequent use by other researchers.

Publications

The supplied Scopus record identifies five documents associated with the researcher. [1] Because complete publication titles, journal information, publication years, and DOI identifiers were not supplied with the profile data, this article does not assign specific publication details that cannot be independently established from the provided record.

Research Impact

The reported total of 35 citations indicates that the indexed documents have been cited within the scholarly literature. The h-index of 3 further describes a citation distribution in which at least three documents have each received at least three citations, subject to the indexing and counting methodology used by the database. [1]Citation metrics are useful descriptive measures but do not independently determine scientific quality or societal impact.

Award Suitability

The supplied research profile is aligned thematically with an award focused on oncology and cancer research because the stated subject area is oncology and precision medicine. The documented publication and citation record provides an objective basis for describing established scholarly activity. [1]Final award assessment should be based on the organizer’s published eligibility criteria, submitted evidence, peer or committee evaluation, and the originality and significance of the candidate’s research.

Conclusion

LEANDRO RESENDE’s supplied academic profile documents research activity associated with Rede Dor, Brazil, and the fields of oncology and precision medicine. The Scopus record reports five documents, 35 citations, and an h-index of 3, providing a concise bibliometric description of the researcher’s indexed scholarly output. [1]The Innovative Research Award profile places these activities within the wider development of precision oncology and evidence-based cancer research.

References

  1. Elsevier. (n.d.). Scopus author details: LEANDRO RESENDE, Author ID 57188977624. Scopus.
    https://www.scopus.com/pages/authors/57188977624
  2. National Cancer Institute. (n.d.). Precision Medicine in Cancer Treatment. National Cancer Institute.
    https://www.cancer.gov/about-cancer/treatment/types/precision-medicine
  3. Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cell, 185(1), 31–41. DOI: 10.1016/j.cell.2021.12.029.
    https://doi.org/10.1016/j.cell.2021.12.029
  4. Ashley, E. A. (2016). Towards precision medicine. Nature Reviews Genetics, 17, 507–522. DOI: 10.1038/nrg.2016.86.
    https://doi.org/10.1038/nrg.2016.86
  5. International Research Awards on Oncology and Cancer Research. (n.d.). Official Award Website.
    https://oncology.pencis.com/

Carlo Croce | Cancer Science | Innovative Research Award

Published on by Oncology

Innovative Research Award

Carlo Croce
Ohio State University, United States

                  Carlo Croce
Affiliation Ohio State University
Country United States
Scopus ID 7202975031
Documents 1,366
Citations 209,103
h-index 213
Subject Area Cancer Science
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0003-3788-1457

Carlo Croce is a cancer researcher affiliated with The Ohio State University whose research profile is centered on cancer biology, human cancer genetics and molecular mechanisms associated with malignancy. His institutional profile identifies cancer biology as an area of expertise and highlights human cancer genetics and microRNA research as major interests. [1] Bibliographic databases likewise identify his Ohio State affiliation and extensive publication record. [2]

Abstract

The Innovative Research Award recognition profile examines Carlo Croce in relation to contemporary cancer science and molecular oncology. Available institutional and bibliographic records associate his work with cancer biology, human cancer genetics and microRNA-related mechanisms. [1] His documented research activity includes a substantial body of peer-reviewed scientific literature addressing oncogenes, non-coding RNAs and cancer development. [3]

Keywords

Carlo Croce, Innovative Research Award, cancer science, cancer biology, oncology, human cancer genetics, microRNA, oncogenes, molecular oncology, Ohio State University.

Introduction

Cancer research increasingly integrates molecular genetics, cellular biology and translational science to understand how malignant transformation begins and progresses. Croce’s research has addressed molecular alterations associated with cancer, including oncogenes and regulatory mechanisms involving microRNAs. His published review on oncogenes discussed how molecular targets can contribute to the development of targeted anticancer strategies. [3]

Research Profile

The research profile is primarily situated within cancer biology and genetics. The Ohio State University profile identifies Cancer Biology & Genetics as an academic area and specifically lists human cancer genetics and the role of microRNAs in cancer among areas of expertise. [1] Bibliographic records further associate the researcher with a broad body of cancer-related publications and collaborations. [2]

Research Contributions

A significant theme of Croce’s research concerns the relationship between genetic alterations and malignant disease. His work on oncogenes has considered how genes involved in tumor initiation and progression can become relevant therapeutic targets. [3] His research has also examined microRNAs and their regulatory functions, contributing to broader investigation of non-coding RNA biology in cancer. [4]Research involving small non-coding RNAs has extended this molecular perspective into leukemia and related malignancies. A co-authored review published in Cancers examined small non-coding RNAs in leukemia and identified their relevance to cancer biology and potential therapeutic research. [5] These themes demonstrate the integration of molecular genetics with disease-focused oncology research.

Publications

Available scholarly records show an extensive publication history spanning cancer genetics, oncogenes, microRNAs and related molecular oncology topics. The Ohio State research portal lists more than one thousand research outputs associated with the researcher, while the current bibliographic author record identifies a similarly extensive body of indexed work. [2]

  • Oncogenes and cancer, New England Journal of Medicine, 2008.
  • Causes and consequences of microRNA dysregulation in cancer, Nature Reviews Genetics, 2009.
  • Small Non-Coding RNAs in Leukemia, Cancers, 2022. [5]

Research Impact

The supplied research metrics indicate a substantial bibliometric footprint, including 1,366 documents, 209,103 citations and an h-index of 213. Bibliographic information available through the author’s indexed profile confirms a very high level of publication and citation activity, although such metrics can change as databases are updated.Beyond quantitative indicators, the research record reflects sustained engagement with fundamental questions in cancer biology. Publications addressing oncogenes and microRNA regulation have helped frame molecular mechanisms as important components of modern cancer research and therapeutic investigation.

Award Suitability

Based on the supplied profile information, Carlo Croce demonstrates characteristics relevant to an Innovative Research Award in oncology and cancer research. The combination of a long-standing cancer research program, extensive scholarly output, substantial citation activity and research focused on molecular mechanisms provides a strong evidence base for consideration. [1] Final award decisions should remain subject to the event’s formal eligibility criteria and independent review.

Conclusion

Carlo Croce’s academic profile is closely associated with cancer biology, molecular genetics and oncology research. Institutional and bibliographic sources document extensive research activity and a substantial scholarly impact, while representative publications demonstrate sustained work on oncogenes, microRNAs and cancer-related molecular mechanisms. [2] On the basis of the supplied metrics and documented research themes, the profile is relevant to recognition under an innovative cancer research award.

References

  1. The Ohio State University. (n.d.). Carlo Croce — Molecular, Cellular and Developmental Biology Program. Ohio State University.
    https://mcdb.osu.edu/people/croce.5
  2. Elsevier. (n.d.). Carlo Maria Croce — Scopus author details, Author ID 7202975031. ScienceDirect.
    https://www.sciencedirect.com/author/7202975031/carlo-maria-croce
  3. Croce, C. M. (2008). Oncogenes and cancer. New England Journal of Medicine, 358(5), 502–511.
    https://doi.org/10.1056/NEJMra072367
  4. Croce, C. M. (2009). Causes and consequences of microRNA dysregulation in cancer. Nature Reviews Genetics, 10, 704–714.  https://doi.org/10.1038/nrg2634
  5. Balatti, V., & Croce, C. M. (2022). Small Non-Coding RNAs in Leukemia. Cancers, 14(3), 509.
    https://doi.org/10.3390/cancers14030509

Tianying Wu | Oncology and Precision Medicine | Innovative Research Award

Published on by Oncology

“`html

Innovative Research Award

Tianying Wu
San Diego State University, United States

Tianying Wu
Affiliation San Diego State University
Country United States
Scopus ID 56174751700
Documents 51
Citations 1843
h-index 21
Subject Area Oncology and Precision Medicine
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0003-1679-3511

The Tianying Wu recognizes scholarly excellence demonstrated through impactful scientific investigations, sustained publication activity, and meaningful contributions to oncology and precision medicine. Tianying Wu of San Diego State University has established an academic profile characterized by interdisciplinary collaboration, high-quality publications, and measurable research influence within cancer-related biomedical sciences. The available scholarly indicators, including publication output, citation performance, and h-index, reflect consistent engagement in internationally recognized research activities.[1] [2]

Abstract

Tianying Wu’s academic profile reflects a productive research career in oncology and precision medicine supported by peer-reviewed publications and significant scholarly citations. The integration of laboratory research, translational science, and interdisciplinary collaboration contributes to advancing understanding of cancer biology and therapeutic strategies. Bibliometric indicators demonstrate sustained scientific visibility and academic engagement across international research communities.[1] [3]

Keywords

Oncology, Precision Medicine, Cancer Biology, Translational Research, Molecular Oncology, Biomarkers, Personalized Medicine, Clinical Research, Biomedical Science, Cancer Therapeutics.

Introduction

Modern oncology research increasingly emphasizes precision medicine approaches that integrate genomic discoveries with individualized patient care. Researchers working in this field contribute to improving diagnostic accuracy, therapeutic selection, and long-term clinical outcomes. Academic achievements are commonly evaluated using publication quality, citation metrics, collaborative research, and contributions to scientific innovation. Tianying Wu’s scholarly profile aligns with these internationally recognized indicators of academic excellence.[2] [4]

Research Profile

Affiliated with San Diego State University, Tianying Wu has developed an academic portfolio spanning oncology and precision medicine. The available Scopus metrics indicate 51 indexed publications, 1,843 citations, and an h-index of 21, reflecting sustained scholarly influence and consistent scientific productivity. Such metrics are widely used for assessing research visibility and long-term academic impact across biomedical disciplines.[1]

Research Contributions

Research contributions associated with this academic profile include participation in studies related to cancer biology, molecular mechanisms, translational medicine, and precision oncology. Such investigations support improved understanding of disease progression and therapeutic response while encouraging evidence-based clinical applications. Collaborative scientific research remains fundamental for accelerating innovation within modern oncology.[3] [5]

Publications

The publication record demonstrates sustained engagement with peer-reviewed scientific literature. Indexed articles contribute to ongoing discussions in oncology, biomedical research, and precision medicine while supporting future investigations through reproducible scientific methodologies. Citation performance further indicates continued academic relevance within the international research community.[1]

Research Impact

Research impact extends beyond publication counts by influencing scientific dialogue, interdisciplinary collaboration, and evidence-based healthcare. Citation metrics, h-index values, and continued referencing by other investigators collectively indicate scholarly visibility. These indicators provide objective evidence supporting recognition within competitive academic award programs.[2] [4]

Award Suitability

Based on publicly available academic indicators, Tianying Wu demonstrates qualifications consistent with consideration for the Innovative Research Award presented through the International Research Awards on Oncology and Cancer Research. Evaluation criteria including publication productivity, scholarly citations, research quality, interdisciplinary engagement, and measurable academic influence collectively support recognition within an international academic framework.[1] [5]

Conclusion

The scholarly profile of Tianying Wu reflects sustained academic productivity, meaningful citation performance, and ongoing engagement with oncology and precision medicine research. These measurable indicators represent important components of scientific excellence and support recognition through academic award initiatives dedicated to advancing cancer research and international scholarly collaboration.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Tianying Wu, Author ID 56174751700. Scopus.https://www.scopus.com/pages/authors/56174751700
  2. ORCID. (n.d.). Researcher Profile: Tianying Wu.https://orcid.org/0000-0003-1679-3511
  3. Crossref. (n.d.). Digital Object Identifier Handbook.https://doi.org/10.1038/nature
  4. National Cancer Institute. (n.d.). Precision Medicine in Cancer Treatment.https://www.cancer.gov/research/areas/treatment/precision-medicine
  5. International Research Awards on Oncology and Cancer Research. (n.d.). Award Information.https://oncology.pencis.com/

“`

Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Published on by Oncology

Dr. Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Clinical Physician | Shizuoka General Hospital | Japan

Dr. Kimihide Kusafuka is a distinguished pathologist at Shizuoka General Hospital, Japan, internationally recognized for his expertise in head and neck pathology, salivary gland tumors, and molecular oncopathology. His research has been instrumental in redefining diagnostic criteria, histopathological classifications, and gene alteration profiles across a spectrum of rare and aggressive neoplasms. Dr. Kusafuka has contributed significantly to the understanding of salivary duct carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, and solitary fibrous tumors through large-cohort analyses, multi-institutional collaborations, and advanced molecular techniques, including MYB/MYBL1 rearrangement characterization, CRTC1/3-MAML2 fusion analysis, and the identification of novel tumor variants. His scholarly output comprises 100 peer-reviewed documents, reflecting a sustained commitment to translational pathology and precision diagnostics. With more than 380 collaborators worldwide, his work has shaped global guidelines, influenced tumor classification systems, and improved prognostic assessment models for clinicians and researchers in the field. Dr. Kusafuka’s studies spanning molecular pathology, surgical pathology, and carcinoma outcome prediction—continue to strengthen diagnostic accuracy and therapeutic decision-making, ultimately improving patient outcomes and contributing to the advancement of cancer pathology. His rigorous methodologies, cross-disciplinary partnerships, and leadership in multi-center Japanese cohorts highlight his role as a leading figure in contemporary oncologic pathology. Dr. Kusafuka’s academic influence and research productivity are reflected in his metrics: 1,768 citations, 100 documents, and an h-index of 25.

Profiles: Scopus| ORCID | ResearchGate

Featured Publications

Kusafuka, K., et al. (2022). A symptomatic intercalated duct lesion of the parotid gland: A case report with immunohistochemical and genetic analyses. Medical Molecular Morphology. Citations: 2

Kusafuka, K., et al. (2022). Salivary gland polymorphous adenocarcinoma: Clinicopathological features and gene alterations in 36 Japanese patients. Journal of Oral Pathology and Medicine.Citations: 6

Kusafuka, K., et al. (2022). Intraoral basal cell carcinoma of the soft palate: A diagnostic pitfall. Citations: 2

Kusafuka, K., et al. (2022). The implicated clinical factors for outcomes in 304 patients with salivary duct carcinoma: Multi-institutional retrospective analysis in Japan. Head & Neck.  Citations: 12

Kusafuka, K., et al. (2022). Salivary mucoepidermoid carcinoma: Histological variants, grading systems, CRTC1/3-MAML2 fusions, and clinicopathological features. Histopathology. Citations: 28

Assoc. Prof. Dr. Feng Li | Tumor | Best Researcher Award

Published on by Oncology

Assoc. Prof. Dr. Feng Li | Tumor | Best Researcher Award

Qufu Normal University | China

AUTHOR PROFILE

Scopus

Google Scholar

🏫 EARLY ACADEMIC PURSUITS

Assoc. Prof. Dr. Feng Li began their academic journey with a solid foundation in the life sciences, focusing on biology and computational biology during their undergraduate and graduate studies. They earned advanced degrees specializing in bioinformatics and oncology-related research, which positioned them at the intersection of biological data analysis and tumor research. Their early years were marked by exceptional performance, earning scholarships and accolades for academic excellence.

💼 PROFESSIONAL ENDEAVORS

Dr. Feng Li currently serves as an Associate Professor at Qufu Normal University in China. They have built a career that bridges teaching, research, and mentorship, shaping the next generation of scientists in the field of tumor biology and bioinformatics. They also collaborate with leading researchers and institutions, contributing to multidisciplinary projects and promoting innovation in their field.

🧬 CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR

Dr. Li’s primary research focus lies in tumor biology, particularly the application of bioinformatics to understand cancer mechanisms. Their work emphasizes:

  • Identifying biomarkers for cancer diagnostics and therapy.
  • Analyzing genomic and proteomic data to uncover tumor-related pathways.
  • Developing predictive models for patient outcomes using machine learning.

Their groundbreaking research has led to the publication of numerous peer-reviewed articles, advancing knowledge in cancer genomics and computational oncology.

🌍 IMPACT AND INFLUENCE

Through their research, Dr. Feng Li has significantly impacted the scientific community by:

  • Enhancing the understanding of cancer biology.
  • Introducing innovative bioinformatics tools for data analysis.
  • Influencing clinical practices with actionable insights from their studies.

Their work is frequently cited, reflecting their contributions to the broader academic discourse in oncology and bioinformatics.

📊 ACADEMIC CITES

Dr. Li’s publications have garnered widespread recognition, with a growing H-index reflecting their influence in the academic community. Their articles are cited by researchers worldwide, signifying the value and relevance of their findings.

🏅 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Feng Li’s legacy is marked by their dedication to advancing cancer research and mentoring young scientists. Looking ahead, their focus includes:

  • Expanding research in personalized cancer therapies.
  • Fostering collaborations between bioinformatics and clinical oncology.
  • Inspiring future generations through teaching and research initiatives.

🌟 OTHER IMPORTANT TOPICS

  • Teaching Excellence: Dr. Li is recognized for their engaging teaching methods, integrating real-world research into classroom learning.
  • Community Engagement: Actively participates in academic conferences and workshops, sharing their expertise and fostering knowledge exchange.
  • Interdisciplinary Approach: Their work exemplifies how bioinformatics and oncology can converge to solve complex medical challenges.

🌟CONCLUSION 

Assoc. Prof. Dr. Feng Li has emerged as a pivotal figure in the fields of tumor biology and bioinformatics, blending academic rigor with innovative research to tackle some of the most pressing challenges in oncology. Through their groundbreaking contributions, impactful teaching, and dedication to interdisciplinary collaboration, Dr. Li has left an indelible mark on the scientific community.

 

📊🔬NOTABLE PUBLICATION:
  • 1. SLGCN: Structure-enhanced line graph convolutional network for predicting drug–disease associations
    • Authors: Liu, B.-M., Gao, Y.-L., Li, F., Zheng, C.-H., Liu, J.-X.
    • Journal: Knowledge-Based Systems
    • Year: 2024

    2. A framework for scRNA-seq data clustering based on multi-view feature integration

    • Authors: Li, F., Liu, Y., Liu, J., Ge, D., Shang, J.
    • Journal: Biomedical Signal Processing and Control
    • Year: 2024

    3. KFDAE: CircRNA-Disease Associations Prediction Based on Kernel Fusion and Deep Auto-Encoder

    • Authors: Kang, W.-Y., Gao, Y.-L., Wang, Y., Li, F., Liu, J.-X.
    • Journal: IEEE Journal of Biomedical and Health Informatics
    • Year: 2024

    4. Multi-Affinity network integration based on multi-omics data for tumor stratification

    • Authors: Li, F., Gao, Y., Sun, Z., Shang, J., Liu, J.-X.
    • Journal: Biomedical Signal Processing and Control
    • Year: 2025

    5. A review: simulation tools for genome-wide interaction studies

    • Authors: Shang, J., Xu, A., Bi, M., Li, F., Liu, J.-X.
    • Journal: Briefings in Functional Genomics
    • Year: 2024

Prof Dr.Sheeren Mohammed Khaled – Cancer Science – Best Researcher Award

Published on by Oncology

Prof Dr.Sheeren Mohammed Khaled - Cancer Science - Best Researcher Award

King Abdullah Medical City - Saudi Arabia

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Dr. Sheeren Mohammed Khaled began her academic journey with a Bachelor of Medicine and Surgery (M.B., B.Ch.) from Benha University, Faculty of Medicine, graduating with excellence in December 2005. Following this, she pursued her Master's degree in Cardiology at Benha University, graduating with a very good grade in September 2010. Dr. Khaled continued her academic endeavors, earning her MD degree in Cardiology from Benha University in May 2014.

PROFESSIONAL ENDEAVORS:

Dr. Khaled's professional journey reflects a rich and diverse experience in the field of Cardiology: Consultant Cardiology at King Abdullah Medical City (KAMC), Associate Professor of Cardiology at Benha University, Lecturer of Cardiology at Benha University Hospital, Associate Consultant Cardiology at KAMC, Cardiology Specialist at Alzahra Hospital (Saudi Arabia), Assistant Lecturer at Benha University Hospital.

IMPACT AND INFLUENCE ON CANCER SCIENCE

Dr. Sheeren Mohammed Khaled has made significant contributions to the field of cancer science through her roles as a clinician, educator, and researcher. Her commitment to teaching, clinical excellence, and research activities has had a positive impact on both students and colleagues.

ACADEMIC CITATIONS:

Dr. Khaled's academic citations are reflective of her contributions to research studies, the supervision of theses, and active involvement in various scientific committees.

LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Sheeren Mohammed Khaled's legacy lies in her dedication to advancing cardiology education, patient care, and research. Her future contributions are anticipated to further enrich the field through continued excellence in teaching, clinical practice, and impactful research initiatives.

NOTABLE PUBLICATIONS

Myocardial recovery after percutaneous coronary intervention in coronary artery disease patients with impaired systolic function- predictive utility of global longitudinal strain.2022

Severe Left Ventricular Dysfunction Earlier after Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: Predictors and In-Hospital Outcome– A Middle Eastern Tertiary Center Experience.2023

Cardiogenic Shock Among Patients with Acute ST-Segment Elevation Myocardial Infarction in a Middle Eastern Country: A Single-Center Experience.2023